2. Design of a future study.

Methods	Allocation: randomised (clearly described). Blinding: single‐blind (outcomes assessor). Duration: up to 1 year. Design: parallel.
Participants	Diagnosis: anyone with schizophrenia for whom there is a dilemma of which drugs to use. N = 300. Age: > 18 years. Sex: all. Exclusion criteria: specific contraindication to evaluated treatments.
Interventions	1. Chlorpromazine: dose of choice. N = 150. 2. Piperacetazine: dose of choice. N = 150.
Outcomes	Global state ‐ clinically important change in global state as defined by each study. Mental state ‐ clinically important change in mental state as defined by each study. Mental state ‐ average change in negative symptoms. Adverse events/effects ‐ incidence of serious adverse events/effects. Adverse events/effects ‐ clinically significant extrapyramidal symptoms. Leaving the study early ‐ for any reason. Costs: cost of services, cost of care. Service outcomes: days in hospital, discharged.